HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

UCB bets $2B on Candid's T cell engager ambitions

Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...

By Endpoints News · May 4, 2026 · via Endpoints News
UCB bets $2B on Candid's T cell engager ambitions

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
DealsBriefing
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
May 1, 2026